| 30/07/26 | 07:00:04 | 30 Jul 2026 | | Q2 and H1 2026 Trading Update |
| 28/07/26 | 07:00:06 | 28 Jul 2026 | | ACCRUFeR® Phase 3 pediatric trial published |
| 30/06/26 | 07:52:15 | 30 Jun 2026 | | Block Listing 6 Monthly Return |
| 18/06/26 | 16:20:59 | 18 Jun 2026 | | Results of 2026 Annual General Meeting |
| 29/05/26 | 09:11:15 | 29 May 2026 | | Total Voting Rights |
| 05/05/26 | 07:00:13 | 5 May 2026 | | Grant of Share Options |
| 01/05/26 | 07:00:05 | 1 May 2026 | | Q1 2026 Trading Update |
| 30/04/26 | 07:01:01 | 30 Apr 2026 | | Total Voting Rights |
| 27/04/26 | 07:00:10 | 27 Apr 2026 | | Enrollment in Phase II Clinical Trial for ACCRUFeR |
| 09/04/26 | 12:30:28 | 9 Apr 2026 | | Audited results for year ended 31 December 2025 |
| 01/04/26 | 09:22:08 | 1 Apr 2026 | | Publication of Report, Reinforcing FDA Approval |
| 31/03/26 | 07:03:00 | 31 Mar 2026 | | Total Voting Rights |
| 31/03/26 | 07:00:14 | 31 Mar 2026 | | EMA approves extension - to include adolescents |
| 03/03/26 | 07:00:10 | 3 Mar 2026 | | Chinese NMPA Accepts MAA Submission for ACCRUFeR® |
| 27/02/26 | 07:00:09 | 27 Feb 2026 | | Total Voting Rights |
| 09/02/26 | 07:00:10 | 9 Feb 2026 | | FDA Grants additional Exclusivity for ACCRUFeR |
| 30/01/26 | 07:05:00 | 30 Jan 2026 | | Total Voting Rights |
| 30/01/26 | 07:00:09 | 30 Jan 2026 | | Approval for ACCRUFeR in China expected in Q1 2026 |
| 21/01/26 | 07:00:08 | 21 Jan 2026 | | Q4 2025 Trading Update |
| 02/01/26 | 11:06:43 | 2 Jan 2026 | | Block listing 6 Monthly Return |
| 02/01/26 | 07:00:02 | 2 Jan 2026 | | Total Voting Rights |
| 22/12/25 | 07:00:07 | 22 Dec 2025 | | FDA approves extension for ACCRUFeR® |
| 18/12/25 | 07:13:12 | 18 Dec 2025 | | Block Listing Application |
| 11/12/25 | 07:00:09 | 11 Dec 2025 | | Shield Wins Gold at Titan Branding Awards |
| 03/12/25 | 07:04:17 | 3 Dec 2025 | | Amends Senior Secured Debt Financing |
| 14/11/25 | 07:03:37 | 14 Nov 2025 | | Initiation of a Phase II Clinical Trial in Japan |
| 11/11/25 | 07:00:10 | 11 Nov 2025 | | ACCRUFeR Pediatric PK Results to be Presented |
| 07/11/25 | 07:03:57 | 7 Nov 2025 | | ACCRUFeR receives Authorisation by Korean Ministry |
| 23/10/25 | 07:00:01 | 23 Oct 2025 | | Q3 2025 Trading Update |
| 14/10/25 | 15:01:57 | 14 Oct 2025 | | Grant of Share Options to Chief Executive Officer |
| 01/10/25 | 08:00:00 | 1 Oct 2025 | | Total Voting Rights |
| 01/10/25 | 07:02:00 | 1 Oct 2025 | | Positive efficacy and tolerance in pediatric trial |
| 15/09/25 | 07:00:10 | 15 Sept 2025 | | £1.5 million placing supporting growth of ACCRUFeR |
| 04/09/25 | 07:03:00 | 4 Sept 2025 | | ACCRUFeR® assigned Priority Review in US by FDA |
| 03/09/25 | 14:17:48 | 3 Sept 2025 | | Interim results for the six months ended 30 Jun 25 |
| 27/08/25 | 07:13:24 | 27 Aug 2025 | | Data published -European Journal of Heart Failure |
| 21/08/25 | 12:06:01 | 21 Aug 2025 | | Interim results for the six months ended 30 Jun 25 |
| 23/07/25 | 07:00:01 | 23 Jul 2025 | | Q2 2025 Trading Update |
| 22/05/25 | 17:06:33 | 22 May 2025 | | Result of AGM |
| 24/04/25 | 07:06:52 | 24 Apr 2025 | | Audited results for the year ended 31 Dec 2024 |
| 22/04/25 | 07:01:15 | 22 Apr 2025 | | Licence Agreement in Japan for ACCRUFeR® |
| 17/04/25 | 11:23:02 | 17 Apr 2025 | | Q1 2025 Trading Update |
| 11/03/25 | 07:00:05 | 11 Mar 2025 | | ACCRUFeR® launched in Canada |
| 13/02/25 | 16:15:00 | 13 Feb 2025 | | PDMR Transaction Notification |
| 13/02/25 | 07:00:08 | 13 Feb 2025 | | Grant of Share Options |
| 05/02/25 | 07:00:01 | 5 Feb 2025 | | Unaudited full year trading update |
| 27/01/25 | 07:00:07 | 27 Jan 2025 | | Anders Lundstrom appointed CEO |
| 24/12/24 | 11:25:00 | 24 Dec 2024 | | Result of General Meeting & Total Voting Rights |
| 23/12/24 | 07:00:05 | 23 Dec 2024 | | Results of RetailBook Offer |
| 06/12/24 | 11:31:00 | 6 Dec 2024 | | RetailBook Offer |
